What the FDA labels say about taking them together
Methylphenidate and risperidone
Methylphenidate's FDA label of July 31, 2026 names risperidone in its drug interactions section, and risperidone's label names methylphenidate too. The risperidone label: “Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).”
Check it at the source: the methylphenidate FDA label on DailyMed (effective July 31, 2026, Lannett Company, LLC); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the methylphenidate label say about risperidone?
Methylphenidate label, drug interactionsRisperidone Prevention or Management Monitor for signs of extrapyramidal symptoms.
Methylphenidate label (Sandoz Inc, September 23, 2025), drug interactionsClinical impact; Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS)
Source: FDA drug label (Methylphenidate, NDA021284), Sandoz Inc, effective September 23, 2025 (SPL set 44386394-d2a3-4483-abe1-6c5c634cc501), via openFDA
Source: FDA drug label (Relexxii, NDA216117), Vertical Pharmaceuticals, LLC, effective September 26, 2025 (SPL set 22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d), via openFDA
Source: FDA drug label (Jornay Pm Extended-Release, NDA209311), Ironshore Pharmaceuticals Inc., effective October 3, 2025 (SPL set d95dede0-b1ff-4489-8f91-3bbe122852bf), via openFDA
Source: FDA drug label (methylphenidate hydrochloride CD), Lannett Company, LLC, effective July 31, 2026 (SPL set e45c75dc-d381-475b-b649-a871c8a36e60), via openFDA; the full label on DailyMed
What does the risperidone label say about methylphenidate?
Risperidone label, drug interactionsMethylphenidate Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methylphenidate | Risperidone | |
|---|---|---|
| Labeled for | ADHD | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.158 per tablet 10 mg tablet | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once